CALA

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.
  • The replay of the webcast will be available on the Companys website for 30 days.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
  • The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
  • Calithera plans to share data from this trial by the first quarter of 2023.
  • Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
  • General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.

MARRIOTT HOTELS DEBUTS IN ONE OF COLOMBIA'S MOST VIBRANT DESTINATIONS WITH THE OPENING OF BARRANQUILLA MARRIOTT HOTEL

Retrieved on: 
Wednesday, August 10, 2022

BETHESDA, Md., Aug. 10, 2022 /PRNewswire/ -- Marriott Hotels, the signature flag of Marriott Bonvoy's 30 extraordinary hotel brands, today announced the opening of the highly-anticipated Barranquilla Marriott Hotel, a tribute to the vibrant city of Barranquilla known as the "Golden Gate of Colombia," surrounded by lush tropical landscapes and the colors of the Colombian Caribbean. Featuring modern, thoughtful design, several food and beverage outlets, a serene outdoor pool, as well as ample meeting space, the new hotel is set to become an ideal destination for global travelers who appreciate the blend of business and leisure travel, while learning and experiencing new cultures.  

Key Points: 
  • We are excited to expand the company's presence in the country with the opening of Barranquilla Marriott Hotel," said Brian King, President, Caribbean and Latin America (CALA), Marriott International.
  • "We are thrilled to bring Marriott Hotels to Barranquilla and continue expanding our global footprint in enriching destinations," said Jason Nuell, Senior Vice President, Premium Brands, Marriott International.
  • Barranquilla Marriott Hotelfeatures two restaurants and one bar, inviting guests to experience local culture through food, music, and the Colombian hospitality.
  • Members can redeem their points for experiences including future stays, Marriott Bonvoy Moments, or through partners for luxurious products from Marriott Bonvoy Boutiques.

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

Retrieved on: 
Monday, August 8, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Companys second quarter 2022 financial results will be released on Monday, August 15, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Companys second quarter 2022 financial results will be released on Monday, August 15, 2022.
  • Company management will host a conference call on Monday, August 15, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
  • The conference call registration and live audio webcast can be accessed via the Investors section of the Companys website at www.calithera.com.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.

Global Contact Center Workforce Optimization Market Share Report 2022: Revenue, Market Share, and Execution of the Estimated 36 Worldwide WFO/WEM Suite Vendors

Retrieved on: 
Friday, August 5, 2022

DUBLIN, Aug. 5, 2022 /PRNewswire/ -- The "2022 Contact Center Workforce Optimization Market Share Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 5, 2022 /PRNewswire/ -- The "2022 Contact Center Workforce Optimization Market Share Report" report has been added to ResearchAndMarkets.com's offering.
  • This report analyzes the revenue, market share, and execution of the estimated 36 worldwide workforce optimization (WFO)/workforce engagement management (WEM) suite vendors for fiscal full-year 2021.
  • WFO/WEM suite vendors generated contact center sales of $2,236.9 million during 2021, an increase of $158.5 million, up 7.6%, from $2,078.4 million in 2020.
  • The 2022 Contact Center Workforce Optimization/Workforce Engagement Management Market Share Report presents and analyzes the market's revenue at the highest level, total company revenue and market share, and then breaks it down by vendor, application, and sector.

2022 Contact Center Workforce Optimization Market Share Report: The Principal Resource for Vendors, Investors, and Members of the Financial Community - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022

The "2022 Contact Center Workforce Optimization Market Share Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2022 Contact Center Workforce Optimization Market Share Report" report has been added to ResearchAndMarkets.com's offering.
  • This report analyzes the revenue, market share, and execution of the estimated 36 worldwide workforce optimization (WFO)/workforce engagement management (WEM) suite vendors for fiscal full-year 2021.
  • WFO/WEM suite vendors generated contact center sales of $2,236.9 million during 2021, an increase of $158.5 million, up 7.6%, from $2,078.4 million in 2020.
  • The 2022 Contact Center Workforce Optimization/Workforce Engagement Management Market Share Report presents and analyzes the market's revenue at the highest level, total company revenue and market share, and then breaks it down by vendor, application, and sector.

Broadband Spending Boom Will Push Market to $23.4 B in 2026, According to Dell'Oro Group

Retrieved on: 
Friday, July 29, 2022

REDWOOD CITY, Calif., July 28, 2022 /PRNewswire/ -- According to a newly published report by Dell'Oro Group, the trusted source for market information about the telecommunications, networks, and data center industries, predicts that sales of PON equipment for fiber-to-the-home deployments, cable broadband access equipment, and fixed wireless CPE will all increase from 2022 to 2026, as service providers look to expand both the reach of their fixed broadband services to customers' homes as well as the quality and reliability of those services within their homes.

Key Points: 
  • "We've made significant upward revisions to our long-term broadband and home networking forecast, said Jeff Heynen, Vice President at Dell'Oro Group.
  • Revenue for Fixed Wireless CPE is expected to reach $5.1 B by 2026, led by shipments of 5G sub-6GHz and 5G Millimeter Wave units.
  • The Dell'Oro Group Broadband Access & Home Networking 5-Year Forecast Report provides a complete overview of the Broadband Access market with tables covering manufacturers' revenue, average selling prices, and port/unit shipments for Cable, DSL, PON, and Fixed Wireless equipment.
  • Dell'Oro Group is a market research firm that specializes in strategic competitive analysis in the telecommunications, enterprise networks, data center infrastructure, and network security markets.

Azion Unveils Edge Computing Application Marketplace

Retrieved on: 
Tuesday, July 26, 2022

PALO ALTO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Azion , a leader in edge computing, today unveiled a new global marketplace , an extensive catalog of integrated partner solutions for the companys leading edge platform.

Key Points: 
  • PALO ALTO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Azion , a leader in edge computing, today unveiled a new global marketplace , an extensive catalog of integrated partner solutions for the companys leading edge platform.
  • The marketplace simplifies access to a global edge network, enabling ISVs, open-source communities, and software developers to provide their solutions through the Azion Edge Platform, which is used by thousands of companies worldwide.
  • Thousands of organizations with more than 100,000 applications leverage Azion to efficiently build and run ultra-low latency edge applications.
  • Azion is a popular edge computing platform that simplifies how companies build, secure, deliver, and observe modern applications anywheredirectly in more than 100 edge locations operated by Azion, or other remote devices, clouds, or on-premise locations.

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

Retrieved on: 
Wednesday, July 13, 2022

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, announced that updates related to the ongoing clinical programs for sapanisertib (CB-228) and mivavotinib (CB-659) will be presented at the upcoming International Association for Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) and the 2022 Pan Pacific Lymphoma Conference, respectively.

Key Points: 
  • The phase 2 trial ( NCT05319028 ), which enrolled its first patient in June, is an open-label study of mivavotinib monotherapy in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma (DLBCL).
  • Data from this trial could position Calithera to initiate a study with registrational intent in biomarker-specific DLBCL populations.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
  • The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.

Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

Retrieved on: 
Wednesday, July 6, 2022

SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced that it has enrolled the first patient in a phase 2 clinical trial of sapanisertib (CB-228) in patients with relapsed/refractory NRF2 (NFE2L2)-mutated squamous non-small cell lung cancer (sqNSCLC).

Key Points: 
  • Sapanisertib is a potent and selective, dual mTORC 1/2 inhibitor that targets a key survival mechanism in tumors harboring these mutations.
  • Our experience enrolling biomarker-driven clinical trials has allowed us to quickly advance sapanisertib since acquiring it from Takeda in the fourth quarter of last year.
  • Sapanisertib has the potential to be a first-in-class treatment for patients with NRF2-mutated squamous lung cancer, a patient population with poor prognosis and high unmet need.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.